PO.MCB08.04 · 分子与细胞生物学

利用单细胞多组学解析胶质母细胞瘤中细胞状态的基因调控

Dissecting gene regulation of cellular states in glioblastoma using single-cell multi-omics

海报缩略图:利用单细胞多组学解析胶质母细胞瘤中细胞状态的基因调控
编号 5919 展板 7 时间 4/21 02:00–05:00 区域 Section 21 主讲 Min Yang, PhD
分会场 Genetic and Transcriptomic Dissection of Cancer Evolution
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Min Yang1, Nicolas L. Gonzalez Castro2, Alexander Jucht1, Sophia Kovatsis1, Channing Pooley1, Sydney Dumont1, Kevin Johnson3, Julie Laffy4, Bo Xia1, Roel Verhaak3, Itay Tirosh5, Mario Suva1

1Department of Pathology and Krantz Family Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA,2Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA,3Yale School of Medicine, Department of Neurosurgery, New Haven, CT,4Broad Institute, Boston, MA,5Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel

摘要 Abstract

中文摘要
胶质母细胞瘤(GBM)是一种无法治愈的侵袭性脑癌,其特征为显著的瘤内和瘤间异质性以及非凡的细胞可塑性。单细胞转录组分析揭示了若干主要细胞状态,包括NPC样、OPC样、GPC样、AC样和MES/缺氧样。然而,支配GBM细胞状态转变的顺式调控网络仍知之甚少。在本研究中,我们对35例IDH野生型GBM样本进行了单细胞染色质可及性图谱分析和多组学分析。首先,我们开发了一种新的scATAC-seq数据分析框架,并重建了六个恶性共识顺式调控元件(CRE)模块。其中四个模块与恶性细胞状态特异性相关,分别对应MES/缺氧样、AC样、OPC样和NPC样身份。有趣的是,周期性细胞在所有四个CRE模块中均表现出广泛开放的染色质,而GPC样细胞在AC样和OPC样状态中均显示可及性,提示其作为一种中间或杂合调控状态的作用。进一步的表观遗传信息量化揭示,NPC样恶性细胞相比其他细胞状态具有更高的调控信息含量。主调控因子富集分析将AP-1转录因子鉴定为分化型(MES/AC样)恶性状态相关CRE模块的关键调控因子,而神经元发育转录因子则富集于干样(NPC/OPC样)状态相关模块中。通过体外功能获得和功能缺失实验,我们筛选并验证了若干调节恶性细胞状态转变的转录因子。此外,我们基于scATAC-seq的拷贝数变异(CNA)分析以高分辨率捕获了GBM的标志性基因组事件,包括EGFR局灶扩增、CDKN2A/B缺失以及CDK4和MDM2扩增。利用这些CNA图谱,我们成功构建了高分辨率的系统发育树,捕获了GBM的克隆架构和演化轨迹。通过整合转录组、染色质可及性和遗传CNA数据,我们阐明了GBM进展和细胞可塑性的演化图景。我们的发现为GBM的调控架构提供了重要见解,并为靶向不同细胞状态的精准治疗奠定了基础框架。
查看英文原文 English abstract
Glioblastoma (GBM) is an incurable and aggressive brain cancer characterized by profound intra- and intertumoral heterogeneity and remarkable cellular plasticity. Single-cell transcriptomic analyses have revealed several major cell states, including NPC-like, OPC-like, GPC-like, AC-like and MES/Hypoxia-like. However, the cis-regulatory networks that govern GBM cell state transitions remain poorly understood. In this study, we performed single-cell chromatin accessibility profiling and multi-omics analysis on 35 GBM IDHwt samples. Firstly, we developed a new scATAC-seq data analysis framework and reconstructed six malignant consensus cis-regulatory element (CRE) modules. Four of these modules were specifically associated with malignant cell states corresponding to the MES/Hypoxia-like, AC-like, OPC-like, and NPC-like identities. Interestingly, cycling cells exhibited broadly open chromatin across all four CRE modules, while GPC-like cells showed accessibility in both the AC-like and OPC-like states, suggesting a role as an intermediate or hybrid regulatory state. Further epigenetic information quantification revealed that NPC-like malignant cells harbor higher regulatory information content compared with other cell states. Master regulator enrichment analysis identified AP-1 transcription factors as key regulators of differentiated (MES/AC-like) malignant state-associated CRE modules, whereas neuronal-development transcription factors were enriched in stem-like (NPC/OPC-like) state-associated modules. Through in vitro gain- and loss-of-function experiments, we screened and validated several transcription factors that modulate malignant cell-state transitions. Additionally, our scATAC-seq-based copy number alteration (CNA) analysis captured hallmark GBM genomic events at high resolution, including EGFR focal amplification, CDKN2A/B deletion, and CDK4 and MDM2 amplifications. Leveraging these CNA profiles, we successfully constructed a high-resolution phylogenetic tree, capturing the clonal architecture and evolutionary trajectory of GBM. By integrating transcriptomic, chromatin accessibility, and genetic CNA data, we elucidated the evolutionary landscape of GBM progression and cellular plasticity. Our findings provide significant insights into the regulatory architecture of GBM and establish a foundational framework for precision therapies targeting distinct cell states.
利益披露 Disclosure
M. Yang, None.. N. L. Gonzalez Castro, None.. A. Jucht, None.. S. Kovatsis, None.. C. Pooley, None.. S. Dumont, None.. K. Johnson, None.. J. Laffy, None.. B. Xia, None.. R. Verhaak, None.. I. Tirosh, None.. M. Suva, None.

← 返回 AACR 2026 检索